Use of plasma levels in evaluation of procainamide dosage.
作者信息
Shaw T R, Kumana C R, Royds R B, Padgham C M, Hamer J
出版信息
Br Heart J. 1974 Mar;36(3):265-70. doi: 10.1136/hrt.36.3.265.
Abstract
摘要
相似文献
1
Use of plasma levels in evaluation of procainamide dosage.
Br Heart J. 1974 Mar;36(3):265-70. doi: 10.1136/hrt.36.3.265.
2
Incidence and management of ventricular arrhythmias after acute myocardial infarction.
Br Heart J. 1969 May;31(3):273-80. doi: 10.1136/hrt.31.3.273.
3
Lidocaine (Xylocaine) as an anti-arrhythmic agent.
Med Lett Drugs Ther. 1971 Jan 8;13(1):1-2.
4
Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
Eur J Clin Pharmacol. 1973 Dec;6(4):245-50. doi: 10.1007/BF00644740.
5
[Therapy of arrhythmias].
Wien Z Inn Med. 1973;54(8-9):384-98.
6
[Tachyarrhythmias caused by acute myocardial infarct].
Med Interna (Bucur). 1970 Dec;22(12):1443-50.
7
8
Bretylium tosylate in treatment of refractory ventricular arrhythmias complicating myocardial infarction.
Br Heart J. 1970 Jan;32(1):21-5. doi: 10.1136/hrt.32.1.21.
9
Comparison of drugs used in management of arrhythmias developing after acute myocardial infarction.
Br Heart J. 1969 Nov;31(6):794.
10
Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.
N Engl J Med. 1969 Dec 4;281(23):1253-60. doi: 10.1056/NEJM196912042812301.
引用本文的文献
1
Acetylator phenotype and the clinical pharmacology of slow-release procainamide.
Br J Clin Pharmacol. 1976 Dec;3(6):1023-6. doi: 10.1111/j.1365-2125.1976.tb00352.x.
2
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.
Br J Clin Pharmacol. 1982 Oct;14(4):529-37. doi: 10.1111/j.1365-2125.1982.tb02024.x.
3
A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
Br J Clin Pharmacol. 1982 Oct;14(4):519-27. doi: 10.1111/j.1365-2125.1982.tb02023.x.
4
Procainamide absorption studies to test the feasibility of using a sustained-release preparation.
Br J Clin Pharmacol. 1975 Dec;2(6):515-9. doi: 10.1111/j.1365-2125.1975.tb00569.x.
5
Adverse reactions to procainamide.
Br J Clin Pharmacol. 1977 Oct;4(5):507-11. doi: 10.1111/j.1365-2125.1977.tb00777.x.
6
Serum procainamide levels as therapeutic guides.
Clin Pharmacokinet. 1977 Nov-Dec;2(6):389-402. doi: 10.2165/00003088-197702060-00001.
7
A pharmacokinetic comparison of two sustained-release oral procainamide preparations.
Br J Clin Pharmacol. 1979 Sep;8(3):267-71. doi: 10.1111/j.1365-2125.1979.tb01013.x.
本文引用的文献
1
Hospital mortality in acute myocardial infarction.
Br Med J. 1968 Jul 20;3(5611):143-6. doi: 10.1136/bmj.3.5611.143.
2
Drug therapy. Serum drug concentrations as therapeutic guides.
N Engl J Med. 1972 Aug 3;287(5):227-31. doi: 10.1056/NEJM197208032870505.
3
Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.
N Engl J Med. 1969 Dec 4;281(23):1253-60. doi: 10.1056/NEJM196912042812301.
4
Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure.
Ann Intern Med. 1973 Feb;78(2):183-93. doi: 10.7326/0003-4819-78-2-183.
5
Arrhythmias and late sudden death after myocardial infarction.
Lancet. 1968 Feb 24;1(7539):386-8. doi: 10.1016/s0140-6736(68)91354-8.
6
Long-term use of procaine amide following acute myocardial infarction.
Circulation. 1973 Jun;47(6):1204-10. doi: 10.1161/01.cir.47.6.1204.
Zotero 插件